IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets.
IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets.
复制标题
DOI：
10.1016/s1471-4906(01)01985-8
复制
发表时间：
2001-08
影响因子：
16.8
通讯作者：
H. Volk;K. Asadullah;G. Gallagher;R. Sabat;G. Grutz
中科院分区：
文献类型：
--
作者：
H. Volk;K. Asadullah;G. Gallagher;R. Sabat;G. Grutz
结论干扰血管细胞和/或白细胞的功能可以阻止慢性炎症性疾病的进展，这是一个古老但更有价值的概念。尽管现有药物可以阻断炎症机制的某些方面，但它们缺乏特异性并产生副作用。因此，血管生物学中的新治疗靶点对于开发更好、更特异的疗法是必要的。上述例子表明了炎症性疾病中涉及的几种新机制。了解调节血管细胞-细胞连接、血管通透性和白细胞迁移的分子和信号转导途径将为特异性抑制炎症性疾病提供新的治疗靶点。
ConclusionsIt is an old, but ever more valuable, concept that interfering with the functions of vascular cells and/or leukocytes can stop the progression of chronic inflammatory diseases. Although existing drugs block some aspects of the inflammatory mechanisms, they lack specificity and produce side-effects. Thus, new therapeutic targets in vascular biology are necessary to allow the development of better and morespecific therapies. The above examples suggest several new mechanisms involved in inflammatory diseases. Understanding the molecules and signaltransduction pathways that regulate vascular cell–cell junctions, vascular permeability and the transmigration of leukocytes will point to novel therapeutic targets for the specific inhibition of inflammatory diseases.